Cargando…

Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand

The tumor-suppressive role of Farnesoid X receptor (FXR) in colorectal tumorigenesis supports restoring FXR expression as a novel therapeutic strategy. However, the complicated signaling network and tumor heterogeneity hinder the effectiveness of FXR agonists in the clinical setting. These difficult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Junhui, Yang, Kui, Zheng, Jianbao, Zhao, Wei, Sun, Xuejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203497/ https://www.ncbi.nlm.nih.gov/pubmed/33046820 http://dx.doi.org/10.1038/s41417-020-00239-8

Ejemplares similares

Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis
por: Yu, Junhui, et al.
Publicado: (2020)

Caenorhabditis Intervention Testing Program: the farnesoid X receptor agonist obeticholic acid does not robustly extend lifespan in nematodes
por: Morshead, Mackenzie L, et al.
Publicado: (2020)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene
por: Li, Shan, et al.
Publicado: (2020)

The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury
por: Ferrigno, Andrea, et al.
Publicado: (2018)

Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity
por: Legrand, Anne-Flore, et al.
Publicado: (2023)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
por: Yu, Junhui, et al.
Publicado: (2022)

Correction: Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression
por: Yu, Junhui, et al.
Publicado: (2023)

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration
por: Li, Guodong, et al.
Publicado: (2015)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Effects and mechanism of the bile acid (farnesoid X) receptor on the Wnt/β-catenin signaling pathway in colon cancer
por: Mao, Jiayu, et al.
Publicado: (2020)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function
por: Fallon, Ciara M., et al.
Publicado: (2022)

Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
por: Wang, Hong, et al.
Publicado: (2018)

Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
por: Gonzalez, Frank J., et al.
Publicado: (2015)

Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis
por: Tschuck, Juliane, et al.
Publicado: (2023)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
por: Bae, Eun Hui, et al.
Publicado: (2014)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Taurocholic Acid and Glycocholic Acid Inhibit Inflammation and Activate Farnesoid X Receptor Expression in LPS-Stimulated Zebrafish and Macrophages
por: Ge, Xutao, et al.
Publicado: (2023)

CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression
por: Yu, Junhui, et al.
Publicado: (2019)

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN
por: LIU, JUN, et al.
Publicado: (2014)

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
por: Liu, Xijun, et al.
Publicado: (2015)

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
por: Jiang, Changtao, et al.
Publicado: (2015)

AKR1B7 Is Induced by the Farnesoid X Receptor and Metabolizes Bile Acids
por: Schmidt, Daniel R., et al.
Publicado: (2011)

Farnesoid X receptor contributes to oleanolic acid‐induced cholestatic liver injury in mice
por: Feng, Hong, et al.
Publicado: (2022)

Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma
por: Gong, Yihang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9u7vs3goohk0db9avmt4abeaoo